A Cationic Nanomicellar Complex of the Quaternary Amphiphilic Amine RC16+ with Fenretinide as a New Multitasking System for Antitumor Therapy

Author:

Orienti Isabella1,Cripe Timothy P.2,Currier Mark A.2,Cavallari Cristina1,Teti Gabriella3,Falconi Mirella3

Affiliation:

1. Department of Pharmacy and Biotechnology, University of Bologna, Via S. Donato 19/2, Bologna, Italy

2. Center for Childhood Cancer and Blood Diseases, Nationwide Children's Hospital, Columbus, Ohio, United States

3. Department for Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, via Irnerio 48, Bologna, Italy

Abstract

: This study investigated the antitumor effect of a new nanomicellar complex obtained by combining the antitumor agent fenretinide with a quaternary amphiphilic amine RC16+ also endowed with antitumor activity. Methods: The complex (Fen-RC16+) strongly improved the aqueous solubility of fenretinide (from 1,71 ± 0.08 µg/ml, pure fenretinide to 1500 ± 164 µg /ml, Fen-RC16+ complex) and provided a cytotoxic effect on SH-SY5Y neuroblastoma cell lines resulting from the intrinsic activity of both the complex components. Moreover, the mean size of the nanomicellar complex (ranging from 20 ± 1.97 nm to 40 ± 3.05 nm) was suitable for accumulation to the tumor site by the enhanced permeability and retention effect and the positive charge provided by the quaternary RC16+ induced adsorption of the complex on the tumor cell surface improving the intracellular concentration of fenretinide. Results: All these characteristics made the Fen-RC16+ complex a multitasking system for antitumor therapy. Conclusion: Indeed its in vivo activity, evaluated on SH-SY5Y xenografts, was strong, and the tumor growth did not resume after the treatment withdrawal.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmaceutical Science

Reference38 articles.

1. Li B.L.; Setyawati M.I.; Chen L.; Xie J.; Ariga K.; Lim C.T.; Garaj S.; Leong D.T.; Directing Assembly and Disassembly of 2D MoS(2) Nanosheets with DNA for Drug Delivery. ACS Appl Mater Interfaces 2017,9(18),15286-15296

2. Vlachogiannis G.; Hedayat S.; Vatsiou A.; Jamin Y.; Fernández-Mateos J.; Khan K.; Lampis A.; Eason K.; Huntingford I.; Burke R.; Rata M.; Koh D.M.; Tunariu N.; Collins D.; Hulkki-Wilson S.; Ragulan C.; Spiteri I.; Moorcraft S.Y.; Chau I.; Rao S.; Watkins D.; Fotiadis N.; Bali M.; Darvish-Damavandi M.; Lote H.; Eltahir Z.; Smyth E.C.; Begum R.; Clarke P.A.; Hahne J.C.; Dowsett M.; de Bono J.; Workman P.; Sadanandam A.; Fassan M.; Sansom O.J.; Eccles S.; Starling N.; Braconi C.; Sottoriva A.; Robinson S.P.; Cunningham D.; Valeri N.; Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 2018,359(6378),920-926

3. Meier-Menches S.M.; Gerner C.; Berger W.; Hartinger C.G.; Keppler B.K.; Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development. Chem Soc Rev 2018,47(3),909-928

4. Chodak G.W.; Rukstalis D.; Kellman H.M.; Williams M.; Phase II study of the retinoid analogue 4-HPR in men with carcinoma of the prostate. J Urol 1993,149,257

5. Veronesi U.; De Palo G.; Marubini E.; Costa A.; Formelli F.; Mariani L.; Decensi A.; Camerini T.; Del Turco M.R.; Di Mauro M.G.; Muraca M.G.; Del Vecchio M.; Pinto C.; D’Aiuto G.; Boni C.; Campa T.; Magni A.; Miceli R.; Perloff M.; Malone W.F.; Sporn M.B.; Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999,91(21),1847-1856

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3